Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.

@article{Denning2013PharmacokineticsSA,
  title={Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.},
  author={Jill M Denning and Melanie T Cornpropst and Stephen D. Flach and M. Michelle Berrey and William T Symonds},
  journal={Antimicrobial agents and chemotherapy},
  year={2013},
  volume={57 3},
  pages={1201-8}
}
To investigate the pharmacokinetics, safety, and tolerability of GS-9851 (formerly PSI-7851), a new nucleotide analog inhibitor of hepatitis C virus (HCV), we conducted a double-blind, parallel, placebo-controlled, randomized, single-ascending-dose study. Healthy subjects received oral doses of 25 to 800 mg GS-9851. Peak concentrations of GS-9851 in plasma were achieved more rapidly than those of the metabolites GS-566500 (formerly PSI-352707) and GS-331007 (formerly PSI-6206), with time to… CONTINUE READING
9 Citations
30 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects

  • J Denning, M Cornpropst, SD Flach, MM Berrey, WT. Symonds
  • Antimicrob. Agents Chemother
  • 2013

A new standard of care for the treatment of chronic HCV infection

  • P Negro
  • Nat . Rev . Gastroenterol . Hepatol .
  • 2011

Similar Papers

Loading similar papers…